The history of certain other NBS conditions and procedures has also been recently reviewed: the discovery of galactose mutarotase (GALM) deficiency in Japan [539]; the measurement of glycosaminoglycans by LC-MS/MS for mucopolysaccharidoses [540]; the development of second-tier LC-MS/MS as part of screening for acylcarnitines, acylglycines, amino acids, and organic acids [541]; the introduction of NBS for ALD and peroxisomal disorders in Japan [542]; and DBS screening for glycogen storage disease type 1a [543,544]. This evidence concerns the gene GALM and adrenoleukodystrophy.